Minor Myocardial Scars in Association with Cardiopulmonary Function after COVID-19.
COVID-19
Cardiopulmonary performance
Myocardial scar
Journal
Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
11
04
2023
medline:
22
8
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Myocardial scars detected by cardiovascular magnetic resonance (CMR) imaging after COVID-19 have caused concerns regarding potential long-term cardiovascular consequences. The objective of this study was to investigate cardiopulmonary functioning in patients with versus without COVID-19-related myocardial scars. In this prospective cohort study, CMR was performed approximately 6 months after moderate-to-severe COVID-19. Before (∼3 months post-COVID-19) and after (∼12 months post-COVID-19) the CMR, patients underwent extensive cardiopulmonary testing with cardiopulmonary exercise tests, 24-h ECG, and echocardiography. We excluded participants with overt heart failure. Post-COVID-19 CMR was available in 49 patients with cardiopulmonary tests at 3 and 12 months after the index hospitalization. Nine (18%) patients had small late gadolinium enhancement-detected myocardial scars. Patients with myocardial scars were older (63.2 ± 13.2 vs. 56.2 ± 13.2 years) and more frequently men (89% vs. 55%) compared to those without scars. Cardiorespiratory fitness was similar in patients with and without scars, i.e., peak oxygen uptake: 82.1 ± 11.5% versus 76.3 ± 22.5% of predicted, respectively (p = 0.46). The prevalence of ventricular premature contractions and arrhythmias was low and not different by the presence of myocardial scar. Cardiac structure and function assessed by echocardiography were similar between the groups, except for a tendency of greater left ventricular mass in those with scars (75 ± 20 vs. 62 ± 14, p = 0.02 and p = 0.08 after adjusting for age and sex). There were no significant associations between myocardial scar and longitudinal changes in cardiopulmonary function from 3 to 12 months. Our findings imply that the presence of minor myocardial scars has limited clinical significance with respect to cardiopulmonary function after COVID-19.
Sections du résumé
BACKGROUND
Myocardial scars detected by cardiovascular magnetic resonance (CMR) imaging after COVID-19 have caused concerns regarding potential long-term cardiovascular consequences.
OBJECTIVE
The objective of this study was to investigate cardiopulmonary functioning in patients with versus without COVID-19-related myocardial scars.
METHODS
In this prospective cohort study, CMR was performed approximately 6 months after moderate-to-severe COVID-19. Before (∼3 months post-COVID-19) and after (∼12 months post-COVID-19) the CMR, patients underwent extensive cardiopulmonary testing with cardiopulmonary exercise tests, 24-h ECG, and echocardiography. We excluded participants with overt heart failure.
RESULTS
Post-COVID-19 CMR was available in 49 patients with cardiopulmonary tests at 3 and 12 months after the index hospitalization. Nine (18%) patients had small late gadolinium enhancement-detected myocardial scars. Patients with myocardial scars were older (63.2 ± 13.2 vs. 56.2 ± 13.2 years) and more frequently men (89% vs. 55%) compared to those without scars. Cardiorespiratory fitness was similar in patients with and without scars, i.e., peak oxygen uptake: 82.1 ± 11.5% versus 76.3 ± 22.5% of predicted, respectively (p = 0.46). The prevalence of ventricular premature contractions and arrhythmias was low and not different by the presence of myocardial scar. Cardiac structure and function assessed by echocardiography were similar between the groups, except for a tendency of greater left ventricular mass in those with scars (75 ± 20 vs. 62 ± 14, p = 0.02 and p = 0.08 after adjusting for age and sex). There were no significant associations between myocardial scar and longitudinal changes in cardiopulmonary function from 3 to 12 months.
CONCLUSION
Our findings imply that the presence of minor myocardial scars has limited clinical significance with respect to cardiopulmonary function after COVID-19.
Identifiants
pubmed: 37231850
pii: 000530942
doi: 10.1159/000530942
pmc: PMC10614250
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-306Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):1407-1416
pubmed: 35147665
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
Br Med J. 1959 Aug 29;2(5147):257-66
pubmed: 13823475
Am Heart J. 2021 Dec;242:61-70
pubmed: 34400140
Circ Cardiovasc Imaging. 2014 Mar;7(2):250-258
pubmed: 24363358
JAMA. 2015 Nov 10;314(18):1945-54
pubmed: 26547466
Eur Heart J. 2021 May 14;42(19):1866-1878
pubmed: 33596594
J Cardiovasc Magn Reson. 2020 Sep 3;22(1):62
pubmed: 32878630
JACC Cardiovasc Imaging. 2023 Apr;16(4):559-562
pubmed: 36526580
Circulation. 2021 Feb 9;143(6):609-612
pubmed: 33332151
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
Circulation. 2022 Apr 12;145(15):1123-1139
pubmed: 35404682